NEW YORK, March 20 – The board of directors of Aclara BioSciences, shares of which are now trading about 11 percent under cash, recently approved a plan designed to prevent a hostile takeover.

In a statement released Monday, Aclara of Mountain View, Calif., said its board of directors approved a plan that would allow shareholders to acquire the right to one one-hundredth of newly created preferred stock at one penny each any time before a person or a group acquires 15 percent or more of the outstanding common stock.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

The New York City medical examiner is overseeing an effort to identify missing persons using DNA, according to the Associated Press.

Nobel laureate Günter Blobel has died at 81, the New York Times reports.

In PNAS this week: mouse model of genetically induced emphysema, gene expression signatures of circulating melanoma cells, and more.

Technology Review reports that 2017 was the year of consumer genetic testing and that it could spur new analysis companies.